Global rheumatology therapeutics market controlled by Enbrel, Humira and Remicade

Press release   •   Dec 20, 2012 12:23 GMT

The global rheumatology therapeutics market has been forecast to increase at a compound annual growth rate (CAGR) of 4.8% over the next six years, increasing from a valuation of $17.1 billion in 2011, to hit a market value of $23.8 billion by 2018.

Despite healthy sales of key medications and the positive market impact of an expanding geriatric population, growth in the global rheumatology therapeutics market is expected to slow in the near future due to the entry of biosimilars.

Enbrel (etanercept), Humira (adalimumab) and Remicade (infliximab) are the major drugs used in rheumatology therapeutics. Enbrel and Humira account for the majority of the market in the US. Enbrel's patent is set to expire in October 2012, although this is not expected to have an immediate impact as biosimilars are not predicted to enter the market until 2016-2017.

In March 2011, the Food and Drug Administration (FDA) approved Benlysta (belimumab) for the treatment of SLE and in July 2011, it was approved by the European Medicines Agency (EMA).

Pfizer's Celebrex, a major drug in the Osteoarthritis (OA) market, posted sales of US$2.5 billion in the fiscal year ending 2011, showing an increase of 6% from the previous year. Equally, gout treatment Uloric will reach annual revenues of US$890m-US$1.4 billion by 2014, according to producers Teijin Pharma.

However, both of these blockbuster drugs will go off patent in 2014, leaving the market open to generic competitors.

In contrast, a first-in-class oral Disease-Modifying Antirheumatic Drug (DMARD) intended for Rheumatoid Arthritis, will make a positive impact on rheumatology market revenues following its expected debut in 2013.

For more information on the global rheumatology therapeutics market, see the latest research: Global Rheumatology Therapeutics Market

Follow us on Twitter @CandMResearch issues news updates and report summaries covering all major industries and sectors. The service provides additional client monitoring and timely alerts to breaking industry and sector news leading the day's business headlines. News articles, written by our staff, contain additional analyst insight, providing value added insight for our readers. News updates and real-time alerts on newly-released market reports are also available from our Facebook page, Twitter feed @CandMResearch and RSS links. We also welcome inquiries from business journalists and the news media.